Cosmos Holdings Launches Proprietary Sky Premium Life Prostatium Supplement for Prostate Health

Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

Designed to prevent and protect against benign prostatic hyperplasia, which affects millions of men worldwide

CHICAGO, IL/ACCESSWIRE/March 28, 2022/ Cosmos Holdings, Inc. (“the company”) (Nasdaq: COSM), an international pharmaceutical company with an exclusive line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, over-the-counter drugs and medical devices, today announced that Sky Premium Life, the exclusive line of nutritional supplements from luxury from Cosmos, launched Prostatium for prostate health.

This innovative formula is designed to improve prostate health, as well as alleviate and prevent symptoms of benign prostatic hyperplasia (BPH). BPH, or enlarged prostate, is a fairly common condition in men. About a third of men are likely to have BPH in their 50s, with the prevalence increasing with age. About 30 million men worldwide and up to 14 million men in the United States alone have symptoms related to BPH. This can cause problems with urine flow or in the kidneys, as well as in the urinary tract and bladder.

“Prostatium was designed to not only protect, but also prevent BPH, which is backed by extensive studies around key ingredients, which we’ve combined into a unique, one-of-a-kind formulation,” commented Greg Siokas, CEO of Cosmos Holdings. “Our formulation includes the highest quality ingredients and is designed to promote men’s overall health and well-being. I would like to express my gratitude to the R&D team, who succeeded in developing a product that is truly unique in its kind.”

Mr. Siokas continued: “Sky Premium Life has already captured a significant share of the Greek market and we are expanding aggressively in Europe and globally. At the same time, we remain focused on enriching our product line by developing class-leading formulations based on proven market research to support the growing global demand for high-quality nutraceuticals. We continue to invest in proprietary supplements with high gross margins and leverage these products through our extensive and established global distribution network as we enter additional markets such as China and North America.”

The supplement is made with the highest quality raw materials and to the highest possible standards. Manufacturing is done under strict pharmaceutical standards and Good Manufacturing Process (GMP) protocols, similar to FDA regulations in the United States. Systematic studies demonstrate that extracts of saw palmetto, nettle root, ganoderma, green tea and pygeum, independently of each other, alleviate the symptoms of BPH, decrease the rate of blood flow urine, limit nocturia and residual urine volume in placebo-controlled patients. studies. Additionally, clinical studies support the ability of these ingredients to slow the growth of BPH, as well as decrease prostate-specific antigen (PSA) levels in men treated with lycopene. Cranberry extract has also been shown to help resolve urinary tract infections and alleviate symptoms of BPH.

About Cosmos Holdings, Inc.

Cosmos Holdings Inc. (Nasdaq:COSM) is an international pharmaceutical company, with a proprietary line of nutraceuticals and a distributor of branded and generic pharmaceuticals, nutraceuticals, over-the-counter drugs and medical devices through a extensive distribution network established in the EU. The Company identifies, acquires, develops and markets products that improve the lives and outcomes of patients and has developed a global distribution platform and is currently expanding across Europe, Asia and North America. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece, Athens, Greece and Harlow, UK. More information is available at and

Forward-looking statements

Except for historical information contained in this press release, matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act. of 1934. , as amended. Statements preceded, followed or otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans” and similar expressions or future or conditional verbs such as “shall”, “should”, “should”, “may” and “could”, are generally forward-looking in nature and not historical fact, although not all forward-looking statements include this who is before. These statements involve unknown risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons beyond the Company’s control, including, but not limited to, the Company’s ability to raise sufficient funding to implement its business plans, the impact of the COVID-19 pandemic on the Company’s business, operations and economy generally, and the Company’s ability to develop and commercialize with success of its exclusive products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available on the SEC’s website ( The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact with Investor Relations:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected]

THE SOURCE: Cosmos Holdings, Inc.

See the source version on

Comments are closed.